Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Haplo-identical Transplantation for SAA, MDS and PNH Using PBSCs and Post-transplant Cyclophosphamide
NCT03520647Phase 2Recruiting
- Sponsor
- National Heart, Lung, and Blood Institute
- Start
- Feb 2019
- Primary completion
- Jun 2027
- Modality
- Stem Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide, peripheral blood stem cells in aplastic anemia, myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), sponsored by National Heart, Lung, and Blood Institute. Started Feb 2019; status: recruiting.
02
Drugs
cyclophosphamideperipheral blood stem cells
03
Conditions
aplastic anemiamyelodysplastic syndrome (MDS)paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03520647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03520647.